Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02127502 · ClinicalTrials.gov registry record
VENUS: Septic Gene Expression Using SeptiCyte
A clinical trial of Sepsis and Systemic Inflammatory Response Syndrome (SIRS), sponsored by Immunexpress.
- Completed
- Registry status
- 379
- Enrollment target
- 6
- Study locations
NCT02127502: Completed study of Sepsis and Systemic Inflammatory Response Syndrome (SIRS), sponsored by Immunexpress.
NCT02127502 is a study of Sepsis and Systemic Inflammatory Response Syndrome (SIRS) that has completed, run by Immunexpress. The registered enrollment target is 379 participants, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02127502, a study of Sepsis and Systemic Inflammatory Response Syndrome (SIRS), has completed, sponsored by Immunexpress.
- COMPLETED
- Registry status
- 379 participants
- Enrollment target
- 6
- Study locations
Study Summary
The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their being hospitalized in an intensive care unit (ICU) within the first 7 days of hospitalization. The primary purpose of the study is to validate SeptiCyte® Lab in this population as compared to: 1) the doctor's impression and 2) existing clinical parameters. The investigators also hope to assess how well a related, new blood test, SeptID® identifies different types of infection, as compared to cultures and other lab tests.
Conditions Studied
Study Locations (6)
Illinois
- Rush University Medical Center - Chicago
- Loyola University Medical Center - Maywood
Georgia
- Grady Memorial Hospital - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
New York
- Northwell Health - New Hyde Park
Utah
- Intermountain Medical Center - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 379 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-12 |
What the finished NCT02127502 record still lists
NCT02127502 is an observational study that tracks outcomes without assigning an intervention. The registered 379 participants enrollment target is mid-sized for trials with a published cap, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 0 interventions.
NCT02127502 lists 6 locations in 5 states (Illinois, Georgia, Maryland).
Frequently Asked Questions
What is clinical trial NCT02127502 about?
NCT02127502 is a clinical study titled "VENUS: Septic Gene Expression Using SeptiCyte". The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their being hospitalized in an intensive care unit (ICU) within the first 7 days ...
What is the current status of trial NCT02127502?
This trial is currently completed. The enrollment target is 379 participants. The study started on 2014-04. Estimated completion is 2016-12.
What conditions does trial NCT02127502 study?
This clinical trial studies the following conditions: Sepsis, Systemic Inflammatory Response Syndrome (SIRS).
Who is sponsoring clinical trial NCT02127502?
This trial is sponsored by Immunexpress, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02127502 being conducted?
This trial has 6 study locations across Georgia, Illinois, Maryland, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02127502's enrollment target sits among peer trials
379 29th of 90 higher than 62 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia